EXCLUSIVE: Oragenics Completes Spray Dry Drug Manufacturing, Intranasal Device Filling For Anticipated Mid-Stage Study For Patients With Brain Injury
Portfolio Pulse from Vandana Singh
Oragenics Inc. (NYSE:OGEN) has completed the manufacturing of its spray-dried drug formulation and intranasal device filling for ONP-002, a treatment for concussions. The company is preparing for a Phase 2a clinical trial in Australia, aiming to enroll 40 patients. The trial will assess the drug's efficacy in reducing negative outcomes after a concussion.
August 21, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oragenics has completed the manufacturing of its ONP-002 drug and device for a Phase 2a trial targeting concussions. This progress could positively impact OGEN's stock as it moves closer to clinical trials.
The completion of drug manufacturing and device filling for ONP-002 is a significant milestone for Oragenics, indicating progress towards clinical trials. This development is likely to be viewed positively by investors, as it demonstrates the company's advancement in its drug pipeline, potentially leading to future revenue if the trials are successful.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100